Amicus Therapeutics Jumps 8.6% Pre-Market After Baird Upgrade
(Bloomberg) -- Amicus rose to $5.80-share on 50.9k shares after Baird analyst Michael Ulz upgraded to outperform from neutral and raised PT to $10 from $7 on pipeline upside potential.
- Says the U.S. regulatory path forward for Galafold "is now clear with a GI study," expected to begin in 2017; full approval likely in 2020
- Says SD-101 offers near-term upside potential with Phase 3 data expected mid-2017; positive results would provide >$ 5-$6 boost
- Additional updates on the Pompe program could drive upside
- FOLD has 6 buys, 1 hold, 0 sells with avg PT $11
- NOTE: Nov. 29: Amicus Chance of Galafold Success Higher After Delay: Chardan
To contact the reporter on this story: Tatiana Darie in New York at tdarie1@bloomberg.net
Alert:
HALISTER1Source: BFW (Bloomberg First Word)
Tickers FOLD US (Amicus Therapeutics Inc)
People Michael Ulz (Robert W Baird & Co Inc)
To de-activate this alert, click
hereUUID: 7947283